GlassScriptPhysician profile
Britney Haymond
NPI 1396224416
$16,047.98
in general payments reported to CMS, 2019-2025
30 companies · $3,624 in 2025
The $3,624 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,684 · 2022: $2,830 · 2023: $3,492 · 2024: $3,418 · 2025: $3,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,527.24 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,587.37 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,915.82 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $1,455.25 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $1,351.01 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $1,257.66 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $1,172.21 | 2021-2025 | Azstarys |
| Lundbeck LLC | $1,043.57 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $1,011.14 | 2021-2023 | Austedo |
| Sunovion Pharmaceuticals INC. | $649.47 | 2021-2022 | |
| Neos Therapeutics, LP | $645.88 | 2021-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Metadate Cd |
| Tris Pharma INC | $465.31 | 2021-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $388.16 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $306.72 | 2024-2025 | Fanapt |
| Noven Therapeutics, LLC | $296.91 | 2021-2024 | Xelstrym, Secuado |
| Alkermes, INC. | $248.91 | 2021-2023 | Lybalvi, Aristada |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $231.15 | 2021-2024 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $205.99 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $190.36 | 2022-2024 | Aplenzin |
| Almatica Pharma LLC | $180.97 | 2023-2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $91.65 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $87.99 | 2023-2024 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $54.22 | 2024-2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $49.57 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $41.15 | 2021-2022 | |
| Indivior INC. | $29.11 | 2025 | Sublocade |
| Neuronetics, INC. | $22.26 | 2024 | Neurostar Tms Therapy System |
| Eisai INC. | $20.14 | 2021 | |
| Merck Sharp & Dohme LLC | $17.12 | 2023 | Belsomra |
| Biogen, INC. | $16.76 | 2025 | Zurzuvae |
| Sage Therapeutics, LLC | $14.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britney Haymond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.